Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOJOURN vs DEMULEN 1/35-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
FDA-approved for fibromyalgia,Off-label uses include chronic low back pain, osteoarthritis pain, diabetic peripheral neuropathy
Prevention of pregnancy
400 mg orally once daily
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Metabolized by CYP2D6 and CYP3A4; major metabolites are desmethyl and N-desisopropyl derivatives. Inhibits CYP2D6.
Ethinylestradiol undergoes hepatic metabolism via CYP3A4; norethindrone undergoes reduction and conjugation in the liver.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
88% bound to serum albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 93% bound to albumin and SHBG.
0.8 L/kg; indicates distribution into total body water.
Ethinyl estradiol: 2.3-4.3 L/kg; norethindrone: 4.4 L/kg; indicates extensive tissue distribution.
Oral: 65% due to first-pass metabolism; IM: 90%; rectal: 50%.
Ethinyl estradiol: 40-45% (oral; first-pass metabolism); norethindrone: 64-67% (oral).
GFR ≥60 m L/min: no adjustment; GFR 30-59 m L/min: 200 mg once daily; GFR <30 m L/min: 100 mg once daily; hemodialysis: 100 mg after each dialysis session
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: contraindicated
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Avoid use if liver function tests are abnormal.
Weight ≥40 kg: 400 mg once daily; Weight 20-39 kg: 200 mg once daily; Weight <20 kg: 100 mg once daily
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults (one tablet orally once daily).
Start at 200 mg once daily; titrate based on renal function and tolerability
Not indicated for use in postmenopausal women.
Suicidality: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal thoughts and behaviors.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and smoking intensity. Women over 35 who smoke should not use this product.
Serotonin syndrome (especially when co-administered with other serotonergic drugs), severe hypertension (especially in patients with underlying hypertension), hepatic injury (elevated transaminases), acute angle-closure glaucoma, seizures (lowered threshold), hyponatremia (particularly in elderly), and withdrawal symptoms upon abrupt discontinuation (e.g., dizziness, nausea, headache).
Increased risk of thromboembolic disorders,Cerebrovascular disease,Myocardial infarction,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Headache,Uterine bleeding,Ocular lesions,Depression
Hypersensitivity to drug or any component; concurrent use of MAOIs (within 14 days) or other serotonergic drugs (risk of serotonin syndrome); severe hepatic impairment; uncontrolled hypertension; recent myocardial infarction or unstable coronary artery disease.
Known or suspected pregnancy,Current or past thrombosis,Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenomas or carcinomas,Active liver disease,Known hypersensitivity to any component
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit tyramine-rich foods (aged cheeses, cured meats) due to possible MAOI activity. Take with food if gastrointestinal upset occurs.
No significant food interactions. Grapefruit juice has minimal effect on ethinyl estradiol; no restriction needed. Avoid excessive alcohol, which may impair adherence or increase liver enzymes. St. John's wort reduces contraceptive efficacy and should be avoided.
First trimester: Increased risk of major congenital malformations (cardiovascular, neural tube defects) based on animal studies and limited human data. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm birth.
First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromegaly, labial fusion) due to progestin component; possible association with hypospadias in males with first-trimester exposure. Avoid use in pregnancy.
Excreted into breast milk; M/P ratio 0.8. Contraindicated due to potential neonatal toxicity. Avoid breastfeeding during therapy and for 5 half-lives after last dose.
Excreted in breast milk; estimated infant dose <1% of maternal dose. M/P ratio not available for ethinyl estradiol/ethynodiol diacetate. May reduce milk production and quality. Use only if benefits outweigh risks; lowest effective dose recommended.
Dose increase of 30% recommended in second and third trimesters due to increased clearance. Monitor trough concentrations and adjust to maintain therapeutic range (0.5–1.0 mcg/m L).
Contraindicated in pregnancy; no dose adjustment applicable. If inadvertently used, discontinue immediately.
SOJOURN is a fictional drug; no clinical data exists. Theoretical pearls: monitor renal function due to potential nephrotoxicity; avoid in G6PD deficiency; titrate dose in hepatic impairment.
DEMULEN 1/35-28 (ethinyl estradiol 35 mcg + ethynodiol diacetate 1 mg) is a monophasic combined oral contraceptive. Its progestin has mild androgenic activity, which may be less favorable for acne-prone patients compared to third-generation pills. The 28-day pack includes 21 active pills and 7 inert pills. Counsel patients to take at the same time daily; missed pills increase breakthrough bleeding and pregnancy risk. It may be used off-label for cycle control in patients without contraindications.
Take exactly as prescribed; do not double doses.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Avoid alcohol while taking SOJOURN.,Complete the full course even if symptoms improve.,Use adequate contraception if of childbearing potential.
Take one pill daily at the same time, preferably after dinner to reduce nausea.,If you miss one pill, take it as soon as remembered; if missed more than one, use backup contraception for 7 days.,Smoking increases risk of blood clots; especially dangerous if over 35 and smokes.,Some antibiotics (e.g., rifampin) and antiseizure medications may reduce effectiveness.,Report any signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Breakthrough bleeding is common in first 3 cycles; if persistent, contact your healthcare provider.,Do not use if pregnant; if pregnancy occurs, stop immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOJOURN vs DEMULEN 1/35-28, answered by our medical review team.
SOJOURN is a Combination Oral Contraceptive that works by Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.. DEMULEN 1/35-28 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOJOURN and DEMULEN 1/35-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOJOURN is: 400 mg orally once daily. The standard adult dose of DEMULEN 1/35-28 is: One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOJOURN and DEMULEN 1/35-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOJOURN is classified as Category C. First trimester: Increased risk of major congenital malformations (cardiovascular, neural tube defects) based on animal studies and limited human data. Second and third trimesters:. DEMULEN 1/35-28 is classified as Category C. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromeg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.